TPST net incomeQ2 2026-$5.24M
TPST net income was -$5.24M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$7.87M a year earlier. For the full fiscal 2025 it was -$26.26M, compared with -$41.84M in fiscal 2024.
Tempest Therapeutics Inc. (TPST) financials
For the twelve months ended Jun 30, 2026, Tempest Therapeutics Inc. reported -$40.47M of net income.
- Net income, TTM
- -$40.47M
- Free cash flow, TTM
- -$20.73M
- Cash
- $779.0K
- Market cap
- $7.2M
FY2016FY2017
FY2016FY2025
FY2016FY2025
TPST revenue and earnings growth
TPST EPSQ2 2026-$0.34
TPST diluted EPS was -$0.34 in fiscal Q2 2026 (ended Jun 30, 2026). For the full fiscal 2025 it was -$6.33.
TPST free cash flowQ2 2026-$2.78M
TPST free cash flow was -$2.78M in fiscal Q2 2026 (ended Jun 30, 2026), compared with -$8.43M a year earlier. For the full fiscal 2025 it was -$26.82M, compared with -$33.46M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $295.0K | $653.0K |
| Cost of revenue | - | - | - | - | - | - | - | - | $790.0K | $5.40M |
| Gross profit | - | - | - | - | - | - | - | - | -$495.0K | -$4.75M |
| Research and development | $12.61M | $28.48M | $17.50M | $22.53M | $17.17M | $14.39M | $27.84M | $14.43M | $14.53M | $21.64M |
| Selling, general and admin | $13.97M | $13.55M | $11.66M | $12.11M | $9.82M | $4.91M | $17.56M | $8.69M | $5.96M | $49.22M |
| Operating income | -$26.57M | -$42.03M | -$29.16M | -$34.64M | -$26.99M | -$19.30M | -$45.40M | -$26.87M | -$84.33M | -$81.01M |
| Interest expense | $207.0K | $1.32M | $1.45M | $1.62M | $1.28M | $0 | - | $134.0K | $288.0K | - |
| Pre-tax income | - | - | - | - | - | - | - | - | -$50.91M | -$82.06M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | - | - | $67.0K | $201.0K |
| Net income | -$26.26M | -$41.84M | -$29.49M | -$35.71M | -$28.30M | -$19.21M | -$44.57M | -$27.19M | -$84.58M | -$82.26M |
| EPS, basic | -$6.33 | -$19.50 | -$24.83 | -$40.17 | -$97.11 | -$533.39 | -$42.25 | -$228.54 | -$4183.53 | -$33.28 |
| EPS, diluted | -$6.33 | -$19.50 | -$24.83 | -$40.17 | -$97.11 | -$533.39 | -$42.25 | -$228.54 | -$4183.53 | -$33.28 |
| Diluted shares | 4.1M | 2.1M | 1.2M | 888,377.462 | 291,561.769 | 36,012.385 | 1.1M | 119,003.923 | 20,217.154 | 2.5M |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $7.71M | $30.71M | $39.67M | $31.60M | $51.83M | $18.82M | $3.24M | $73.77M | $17.62M | $41.95M |
| Short-term investments | - | - | - | - | - | - | - | - | $51.50M | $70.46M |
| Current assets | $8.27M | $31.47M | $40.36M | $32.95M | $68.96M | $19.82M | $71.13M | $83.42M | $19.74M | $116.44M |
| Total assets | $16.93M | $41.49M | $51.60M | $46.09M | $73.24M | $22.86M | $74.97M | $84.07M | $19.81M | $122.54M |
| Current liabilities | $3.31M | $14.22M | $9.41M | $7.28M | $20.03M | $3.22M | $12.52M | $9.82M | $4.09M | $13.21M |
| Short-term debt | $0 | $6.35M | $4.29M | - | - | $239.0K | $208.0K | $189.0K | $174.0K | - |
| Long-term debt | - | $0 | $6.26M | $10.37M | $15.07M | $0 | $168.0K | $383.0K | $599.0K | - |
| Total debt | - | $6.35M | $10.55M | $10.37M | $15.07M | $239.0K | $376.0K | $572.0K | $773.0K | - |
| Total liabilities | $10.26M | $22.36M | $24.84M | $27.98M | $37.12M | $4.95M | $15.10M | $10.95M | $4.83M | $14.32M |
| Shareholders' equity | $6.67M | $19.13M | $26.77M | $18.11M | $36.12M | -$68.79M | -$50.36M | $73.12M | -$128.52M | -$51.20M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$26.82M | -$33.03M | -$27.36M | -$31.07M | -$25.96M | -$19.02M | -$41.22M | -$23.65M | -$20.34M | -$61.73M |
| Capital expenditures | $0 | $435.0K | $170.0K | $562.0K | $135.0K | $50.0K | $397.0K | $36.0K | $4.0K | $2.59M |
| Free cash flow | -$26.82M | -$33.46M | -$27.53M | -$31.63M | -$26.09M | -$19.07M | -$41.62M | -$23.68M | -$20.34M | -$64.32M |
| Investing cash flow | $0 | -$435.0K | -$170.0K | -$562.0K | -$97.0K | -$6.0K | $3.99M | $1.93M | $458.0K | $8.29M |
| Financing cash flow | $4.26M | $24.50M | $35.60M | $11.40M | $59.06M | $34.60M | $26.94M | $77.74M | -$4.46M | $54.15M |
| Stock-based compensation | - | - | - | - | - | - | - | - | $6.89M | $9.21M |
| Depreciation and amortization | - | - | - | - | - | - | - | - | $1.65M | $2.24M |
Key ratios
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | Dec 31, 2018 | Dec 31, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | - | - | - | - | - | - | -54.8% | 135.7% |
| Gross margin | - | - | - | - | - | - | - | - | -167.8% | -727.1% |
| Operating margin | - | - | - | - | - | - | - | - | -28585.1% | -12406.1% |
| Net margin | - | - | - | - | - | - | - | - | -28670.5% | -12597.2% |
| Free cash flow margin | - | - | - | - | - | - | - | - | -6896.3% | -9849.9% |
| Return on equity | -393.9% | -218.8% | -110.2% | -197.2% | -78.4% | - | - | -37.2% | - | - |
| Return on assets | -155.1% | -100.9% | -57.1% | -77.5% | -38.6% | -84.0% | -59.4% | -32.3% | -426.9% | -67.1% |
| Current ratio | 2.50 | 2.21 | 4.29 | 4.53 | 3.44 | 6.15 | 5.68 | 8.50 | 4.82 | 8.82 |
| Debt to equity | - | 0.33 | 0.39 | 0.57 | 0.42 | - | - | 0.01 | - | - |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $1.82M | $114.0K | $539.0K | $570.0K | $3.87M | $7.63M | $10.74M | $7.56M | $5.84M | $4.34M | $4.18M | $4.22M |
| Selling, general and admin | $3.43M | $5.42M | $3.54M | $3.03M | $4.09M | $3.31M | $3.18M | $2.99M | $3.75M | $3.63M | $3.33M | $2.37M |
| Operating income | -$5.25M | -$27.72M | -$4.08M | -$3.60M | -$7.97M | -$10.94M | -$13.92M | -$10.55M | -$9.58M | -$7.97M | -$7.51M | -$6.59M |
| Interest expense | $0 | $0 | $0 | $0 | $46.0K | $161.0K | $247.0K | $329.0K | $372.0K | $368.0K | $377.0K | $373.0K |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$5.24M | -$27.70M | -$4.02M | -$3.51M | -$7.87M | -$10.86M | -$13.81M | -$10.56M | -$9.57M | -$7.90M | -$7.49M | -$6.79M |
| EPS, basic | -$0.34 | -$2.53 | - | -$0.79 | -$2.07 | -$3.16 | - | -$5.32 | -$5.52 | -$4.62 | -$4.42 | -$6.24 |
| EPS, diluted | -$0.34 | -$2.53 | - | -$0.79 | -$2.07 | -$3.16 | - | -$5.32 | -$5.52 | -$4.62 | -$4.42 | -$6.24 |
| Diluted shares | 15.2M | 10.9M | - | 4.4M | 3.8M | 3.4M | - | 2.0M | 1.7M | 1.7M | - | 1.1M |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $779.0K | $1.80M | $7.71M | $7.51M | $14.72M | $21.95M | $30.71M | $22.91M | $31.57M | $32.77M | $39.67M | $11.51M |
| Current assets | $1.70M | $2.45M | $8.27M | $8.10M | $15.10M | $22.43M | $31.47M | $23.55M | $31.55M | $33.50M | $40.36M | $12.29M |
| Total assets | $9.63M | $10.75M | $16.93M | $17.13M | $24.48M | $32.16M | $41.49M | $33.84M | $42.17M | $44.38M | $51.60M | $23.99M |
| Current liabilities | $4.45M | $3.31M | $3.31M | $3.52M | $7.14M | $13.18M | $14.22M | $13.97M | $14.56M | $10.69M | $9.41M | $7.42M |
| Short-term debt | - | - | $0 | $0 | $0 | $4.19M | $6.35M | $8.50M | $8.64M | $6.46M | $4.29M | $2.13M |
| Long-term debt | - | - | - | - | - | - | $0 | $0 | $2.01M | $4.14M | $6.26M | $8.37M |
| Total debt | - | - | - | - | - | $4.20M | $6.35M | $8.50M | $10.65M | $10.60M | $10.55M | $10.51M |
| Total liabilities | $10.72M | $9.93M | $10.26M | $10.78M | $14.70M | $21.03M | $22.36M | $22.38M | $25.23M | $23.75M | $24.84M | $25.18M |
| Shareholders' equity | -$1.09M | $822.0K | $6.67M | $6.35M | $9.78M | $11.13M | $19.13M | $11.46M | $16.94M | $20.63M | $26.77M | -$1.19M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.78M | -$7.60M | -$3.57M | -$6.78M | -$8.43M | -$8.04M | -$10.15M | -$10.18M | -$5.51M | -$7.19M | -$6.17M | -$6.49M |
| Capital expenditures | $0 | $0 | $0 | $0 | $0 | $0 | $3.0K | $15.0K | $249.0K | $168.0K | $7.0K | $0 |
| Free cash flow | -$2.78M | -$7.60M | -$3.57M | -$6.78M | -$8.43M | -$8.04M | -$10.15M | -$10.20M | -$5.76M | -$7.35M | -$6.18M | -$6.49M |
| Investing cash flow | $0 | $0 | $0 | $0 | $0 | $0 | -$3.0K | -$15.0K | -$249.0K | -$168.0K | -$7.0K | $0 |
| Financing cash flow | $1.75M | $1.70M | $3.77M | $13.0K | $1.20M | -$721.0K | $17.95M | $1.54M | $4.56M | $450.0K | $34.35M | $21.0K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 0.38 | 0.74 | 2.50 | 2.30 | 2.11 | 1.70 | 2.21 | 1.69 | 2.17 | 3.13 | 4.29 | 1.66 |
| Debt to equity | - | - | - | - | - | 0.38 | 0.33 | 0.74 | 0.63 | 0.51 | 0.39 | - |
Source: XBRL data Tempest Therapeutics Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-13, first reported May 13, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
TPST peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| TPST | - | - | -$40.47M | - | $7.2M |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.33T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $679.13B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $518.44B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $366.73B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $312.35B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $293.69B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.40B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $183.23B |
TPST FAQ
5 questionsIs TPST profitable?
No. Tempest Therapeutics Inc. reported a net loss of $40.47M for the twelve months ended Jun 30, 2026.How much cash and debt does TPST have?
Tempest Therapeutics Inc. reported $779.0K in cash and cash equivalents on its most recent balance sheet in SEC filings.What is TPST free cash flow?
Tempest Therapeutics Inc. generated -$20.73M of free cash flow for the twelve months ended Jun 30, 2026, which is operating cash flow of -$20.73M less capital expenditures.When did TPST last report financial results?
The latest statements here come from Tempest Therapeutics Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this TPST financial data come from?
Quantisnow builds these statements from the structured XBRL data Tempest Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.